TROUBLE

Veterinary Report by Embark

embarkvet.com

Test Date: March 12th, 2021

Customer-supplied information

Owner Name: Amy Dettore

Dog Name: Trouble Sex: Male (intact) Date of birth: 05/14/19 Breed type: n/a

Breed: Cavalier King Charles Spaniel Breed registration: AKC TS42341207

Microchip: n/a

Genetic summary

Genetic breed identification:

Cavalier King Charles Spaniel

Predicted adult weight: **22 lbs** Calculated from 17 size genes.

Genetic age: 24 human years

Human equivalent age based on size, date of

birth provided, and other factors

Clinical Tools

These clinical genetic tools can inform clinical decisions and diagnoses. These tools do not predict increased risk for disease.

Alanine Aminotransferase Activity (GPT)

Trouble's baseline ALT level is Low Normal

Why is this important to your vet?

Trouble has one copy of a variant associated with reduced ALT activity as measured on veterinary blood chemistry panels. Please inform your veterinarian that Trouble has this genotype, as ALT is often used as an indicator of liver health and Trouble is likely to have a lower than average resting ALT activity. As such, an increase in Trouble's ALT activity could be evidence of liver damage, even if it is within normal limits by standard ALT reference ranges.

What is Alanine Aminotransferase Activity?

Alanine aminotransferase (ALT) is a clinical tool that can be used by veterinarians to better monitor liver health. This result is not associated with liver disease. ALT is one of several values veterinarians measure on routine blood work to evaluate the liver. It is a naturally occurring enzyme located in liver cells that helps break down protein. When the liver is damaged or inflamed, ALT is released into the bloodstream.

How vets diagnose this condition

Genetic testing is the only way to provide your veterinarian with this clinical tool.

How this condition is treated

Veterinarians may recommend blood work to establish a baseline ALT value for healthy dogs with one or two copies of this variant.

Health Report

How to interpret Trouble's genetic health results:

If Trouble inherited any of the variants that we tested, they will be listed at the top of the Health Report section, along with a description of how to interpret this result. We also include all of the variants that we tested Trouble for that we did not detect the risk variant for.

A genetic test is not a diagnosis

This genetic test does not diagnose a disease. Please talk to your vet about your dog's genetic results, or if you think that your pet may have a health condition or disease.



Trouble is at increased risk for one genetic health condition.

And inherited one variant that you should learn more about.

Chondrodystrophy and Intervertebral Disc Disease, CDDY/IVDD, Type I IVDD	٥
Degenerative Myelopathy, DM	0
Breed-Relevant Genetic Conditions 3 varia	nnts not detected
Additional Genetic Conditions 194 varia	nnts not detected

Health Report

Chondrodystrophy and Intervertebral Disc Disease, CDDY/IVDD, Type I IVDD (FGF4 retrogene - CFA12)

Trouble inherited both copies of the variant we tested
Trouble is at increased risk for Type I IVDD

How to interpret this result

Trouble has two copies of an FGF4 retrogene on chromosome 12. In some breeds such as Beagles, Cocker Spaniels, and Dachshunds (among others) this variant is found in nearly all dogs. While those breeds are known to have an elevated risk of IVDD, many dogs in those breeds never develop IVDD. For mixed breed dogs and purebreds of other breeds where this variant is not as common, risk for Type I IVDD is greater for individuals with this variant than for similar dogs.

What is Chondrodystrophy and Intervertebral Disc Disease, CDDY/IVDD, Type I IVDD?

Type I Intervertebral Disc Disease (IVDD) is a back/spine issue that refers to a health condition affecting the discs that act as cushions between vertebrae. With Type I IVDD, affected dogs can have a disc event where it ruptures or herniates towards the spinal cord. This pressure on the spinal cord causes neurologic signs which can range from a wobbly gait to impairment of movement. Chondrodystrophy (CDDY) refers to the relative proportion between a dog's legs and body, wherein the legs are shorter and the body longer. There are multiple different variants that can cause a markedly chondrodystrophic appearance as observed in Dachshunds and Corgis. However, this particular variant is the only one known to also increase the risk for IVDD.

When signs & symptoms develop in affected dogs

Signs of CDDY are recognized in puppies as it affects body shape. IVDD is usually first recognized in adult dogs, with breed specific differences in age of onset.

Signs & symptoms

Research indicates that dogs with one or two copies of this variant have a similar risk of developing IVDD. However, there are some breeds (e.g. Beagles and Cocker Spaniels, among others) where this variant has been passed down to nearly all dogs of the breed and most do not show overt clinical signs of the disorder. This suggests that there are other genetic and environmental factors (such as weight, mobility, and family history) that contribute to an individual dog's risk of developing clinical IVDD. Signs of IVDD include neck or back pain, a change in your dog's walking pattern (including dragging of the hind limbs), and paralysis. These signs can be mild to severe, and if your dog starts exhibiting these signs, you should schedule an appointment with your veterinarian for a diagnosis.

How vets diagnose this condition

For CDDY, dogs with one copy of this variant may have mild proportional differences in their leg length. Dogs with two copies of this variant will often have visually longer bodies and shorter legs. For IVDD, a neurological exam will be performed on any dog showing suspicious signs. Based on

the result of this exam, radiographs to detect the presence of calcified discs or advanced imaging (MRI/CT) to detect a disc rupture may be recommended.

How this condition is treated

IVDD is treated differently based on the severity of the disease. Mild cases often respond to medical management which includes cage rest and pain management, while severe cases are often treated with surgical intervention. Both conservative and surgical treatment should be followed up with rehabilitation and physical therapy.

Actions to take if your dog is affected

- Follow veterinary advice for diet, weight management, and daily exercise. Overweight dogs and those with insufficient exercise are thought to be at higher risk of developing clinical disease.
- Ramps up to furniture, avoiding flights of stairs, and using a harness on walks will also help minimize some of the risk of an IVDD event by reducing stress on the back.
- In breeds where this variant is extremely common, this genetic health result should not be a deciding factor when evaluating a dog for breeding or adoption purposes.

Health Report

Degenerative Myelopathy, DM (SOD1A)

Trouble inherited one copy of the variant we tested

What does this result mean?

This result should not impact Trouble's health but it could have consequences for siblings or other related dogs if they inherited two copies of the variant. We recommend discussing this result with their owners or breeders if you are in contact.

Impact on Breeding

This result should be taken into account as part of your breeding program. Trouble will pass this variant to \sim 50% of his offspring.

What is Degenerative Myelopathy, DM?

The dog equivalent of Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease, DM is a progressive degenerative disorder of the spinal cord. Because the nerves that control the hind limbs are the first to degenerate, the most common clinical signs are back muscle wasting and gait abnormalities.

When signs & symptoms develop in affected dogs

Affected dogs do not usually show signs of DM until they are at least 8 years old.

How vets diagnose this condition

Definitive diagnosis requires microscopic analysis of the spinal cord after death. However, veterinarians use clues such as genetic testing, breed, age, and other diagnostics to determine if DM is the most likely cause of your dog's clinical signs.

How this condition is treated

As dogs are seniors at the time of onset, the treatment for DM is aimed towards increasing their comfort through a combination of lifestyle changes, medication, and physical therapy.

Actions to take if your dog is affected

• Giving your dog the best quality of life for as long as possible is all you can do after receiving this diagnosis.

Breed-Relevant Conditions Tested



Trouble did not have the variants that we tested for, that are relevant to his breed:

- **⊘** Congenital Keratoconjunctivitis Sicca and Ichthyosiform Dermatosis, Dry Eye Curly Coat Syndrome, CKCSID (FAM83H Exon 5)
- Muscular Dystrophy (DMD, Cavalier King Charles Spaniel Variant 1)
- Episodic Falling Syndrome (BCAN)



Trouble did not have the variants that we tested for, in the following conditions that the potential effect on dogs with Trouble's breed may not yet be known.

- MDR1 Drug Sensitivity (MDR1)
- P2Y12 Receptor Platelet Disorder (P2Y12)
- Factor IX Deficiency, Hemophilia B (F9 Exon 7, Terrier Variant)
- Factor IX Deficiency, Hemophilia B (F9 Exon 7, Rhodesian Ridgeback Variant)
- ▼ Factor VII Deficiency (F7 Exon 5)
- Factor VIII Deficiency, Hemophilia A (F8 Exon 10, Boxer Variant)
- Factor VIII Deficiency, Hemophilia A (F8 Exon 11, Shepherd Variant 1)
- Factor VIII Deficiency, Hemophilia A (F8 Exon 1, Shepherd Variant 2)
- Thrombopathia (RASGRP1 Exon 5, Basset Hound Variant)
- ▼ Thrombopathia (RASGRP1 Exon 8)
- ▼ Thrombopathia (RASGRP1 Exon 5, American Eskimo Dog Variant)
- Von Willebrand Disease Type III, Type III vWD (VWF Exon 4)
- Von Willebrand Disease Type III, Type III vWD (VWF Exon 7)
- **▼** Von Willebrand Disease Type I (VWF)
- **⊘** Von Willebrand Disease Type II, Type II vWD (VWF)
- Canine Leukocyte Adhesion Deficiency Type I, CLADI (ITGB2)
- Canine Leukocyte Adhesion Deficiency Type III, CLADIII (FERMT3)
- Congenital Macrothrombocytopenia (TUBB1 Exon 1, Cairn and Norfolk Terrier Variant)
- Canine Elliptocytosis (SPTB Exon 30)
- ✓ Glanzmann's Thrombasthenia Type I (ITGA2B Exon 12)
- May-Hegglin Anomaly (MYH9)
- Prekallikrein Deficiency (KLKB1 Exon 8)
- Pyruvate Kinase Deficiency (PKLR Exon 5)
- Pyruvate Kinase Deficiency (PKLR Exon 7 Labrador Variant)

- Pyruvate Kinase Deficiency (PKLR Exon 7 Pug Variant)
- Pyruvate Kinase Deficiency (PKLR Exon 7 Beagle Variant)
- Pyruvate Kinase Deficiency (PKLR Exon 10)
- ▼ Trapped Neutrophil Syndrome (VPS13B)
- ✓ Ligneous Membranitis, LM (PLG)
- Platelet factor X receptor deficiency, Scott Syndrome (TMEM16F)
- Methemoglobinemia CYB5R3
- Congenital Hypothyroidism (TPO, Tenterfield Terrier Variant)
- Congenital Hypothyroidism (TPO, Rat, Toy, Hairless Terrier Variant)
- Complement 3 Deficiency, C3 Deficiency (C3)
- Severe Combined Immunodeficiency (PRKDC)
- Severe Combined Immunodeficiency (RAG1)
- X-linked Severe Combined Immunodeficiency (IL2RG Variant 1)
- X-linked Severe Combined Immunodeficiency (IL2RG Variant 2)
- Progressive Retinal Atrophy, rcd1 (PDE6B Exon 21 Irish Setter Variant)
- Progressive Retinal Atrophy, rcd3 (PDE6A)
- Progressive Retinal Atrophy, CNGA (CNGA1 Exon 9)
- Progressive Retinal Atrophy, prcd (PRCD Exon 1)
- Progressive Retinal Atrophy (CNGB1)
- Progressive Retinal Atrophy (SAG)
- **☑** Golden Retriever Progressive Retinal Atrophy 1, GR-PRA1 (SLC4A3)
- **☑** Golden Retriever Progressive Retinal Atrophy 2, GR-PRA2 (TTC8)
- Progressive Retinal Atrophy, crd1 (PDE6B)
- Progressive Retinal Atrophy crd4/cord1 (RPGRIP1)

- X-Linked Progressive Retinal Atrophy 1, XL-PRA1 (RPGR)
- Progressive Retinal Atrophy, PRA3 (FAM161A)
- Collie Eye Anomaly, Choroidal Hypoplasia, CEA (NHEJ1)
- ✓ Day blindness, Cone Degeneration, Achromatopsia (CNGB3 Exon 6)
- Achromatopsia (CNGA3 Exon 7 German Shepherd Variant)
- Achromatopsia (CNGA3 Exon 7 Labrador Retriever Variant)
- Autosomal Dominant Progressive Retinal Atrophy (RHO)
- Canine Multifocal Retinopathy (BEST1 Exon 2)
- Canine Multifocal Retinopathy (BEST1 Exon 5)
- Canine Multifocal Retinopathy (BEST1 Exon 10 Deletion)
- Canine Multifocal Retinopathy (BEST1 Exon 10 SNP)
- **⊘** Glaucoma (ADAMTS10 Exon 9)
- Glaucoma (ADAMTS10 Exon 17)
- **☑** Glaucoma (ADAMTS17 Exon 11)
- Glaucoma (ADAMTS17 Exon 2)
- **♥** Goniodysgenesis and Glaucoma (OLFM3)
- Hereditary Cataracts, Early-Onset Cataracts, Juvenile Cataracts (HSF4 Exon 9 Shepherd Variant)
- Primary Lens Luxation (ADAMTS17)
- Congenital Stationary Night Blindness (RPE65)
- Congenital Stationary Night Blindness (LRIT3)
- Macular Corneal Dystrophy, MCD (CHST6)
- 2,8-Dihydroxyadenine Urolithiasis, 2,8-DHA Urolithiasis (APRT)
- Cystinuria Type I-A (SLC3A1)
- Cystinuria Type II-A (SLC3A1)

- Cystinuria Type II-B (SLC7A9)
- Hyperuricosuria and Hyperuricemia or Urolithiasis, HUU (SLC2A9)
- Polycystic Kidney Disease, PKD (PKD1)
- Primary Hyperoxaluria (AGXT)
- Protein Losing Nephropathy, PLN (NPHS1)
- X-Linked Hereditary Nephropathy, XLHN (COL4A5 Exon 35, Samoyed Variant 2)
- ✓ Primary Ciliary Dyskinesia, PCD (CCDC39 Exon 3)
- Primary Ciliary Dyskinesia, PCD (NME5)
- X-linked Ectodermal Dysplasia, Anhidrotic Ectodermal Dysplasia (EDA Intron 8)
- Renal Cystadenocarcinoma and Nodular Dermatofibrosis, RCND (FLCN Exon 7)
- Canine Fucosidosis (FUCA1)
- **☑** Glycogen Storage Disease Type IA, Von Gierke Disease, GSD IA (G6PC)
- ✓ Glycogen Storage Disease Type IIIA, GSD IIIA (AGL)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 1)
- Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 2)
- Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 5)
- Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 3)
- Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Whippet and English Springer Spaniel Variant)
- Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Wachtelhund Variant)
- **▼** Lagotto Storage Disease (ATG4D)
- Neuronal Ceroid Lipofuscinosis 1, NCL 1 (PPT1 Exon 8)
- Neuronal Ceroid Lipofuscinosis 2, NCL 2 (TPP1 Exon 4)

- Neuronal Ceroid Lipofuscinosis 1, Cerebellar Ataxia, NCL4A (ARSG Exon 2)
- Neuronal Ceroid Lipofuscinosis 1, NCL 5 (CLN5 Border Collie Variant)
- Neuronal Ceroid Lipofuscinosis 6, NCL 6 (CLN6 Exon 7)
- Neuronal Ceroid Lipofuscinosis 8, NCL 8 (CLN8 English Setter Variant)
- Neuronal Ceroid Lipofuscinosis (MFSD8)
- Neuronal Ceroid Lipofuscinosis (CLN8 Australian Shepherd Variant)
- Neuronal Ceroid Lipofuscinosis 10, NCL 10 (CTSD Exon 5)
- Neuronal Ceroid Lipofuscinosis (CLN5 Golden Retriever Variant)
- Adult-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Tibetan Terrier Variant)
- ✓ Late-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Australian Cattle Dog Variant)
- **☑** GM1 Gangliosidosis (GLB1 Exon 15 Shiba Inu Variant)
- GM1 Gangliosidosis (GLB1 Exon 15 Alaskan Husky Variant)
- **◯** GM1 Gangliosidosis (GLB1 Exon 2)
- **✓** GM2 Gangliosidosis (HEXB, Poodle Variant)
- **◯** GM2 Gangliosidosis (HEXA)
- Globoid Cell Leukodystrophy, Krabbe disease (GALC Exon 5)
- Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Italian Greyhound Variant)
- Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Parson Russell Terrier Variant)
- Persistent Mullerian Duct Syndrome, PMDS (AMHR2)
- Deafness and Vestibular Syndrome of Dobermans, DVDob, DINGS (MYO7A)
- Shar-Pei Autoinflammatory Disease, SPAID, Shar-Pei Fever (MTBP)
- Neonatal Interstitial Lung Disease (LAMP3)
- Alaskan Husky Encephalopathy, Subacute Necrotizing Encephalomyelopathy (SLC19A3)
- Alexander Disease (GFAP)

- Cerebellar Abiotrophy, Neonatal Cerebellar Cortical Degeneration, NCCD (SPTBN2)
- Cerebellar Ataxia, Progressive Early-Onset Cerebellar Ataxia (SEL1L)
- Cerebellar Hypoplasia (VLDLR)
- Spinocerebellar Ataxia, Late-Onset Ataxia, LoSCA (CAPN1)
- Spinocerebellar Ataxia with Myokymia and/or Seizures (KCNJ10)
- Hereditary Ataxia (RAB24)
- Benign Familial Juvenile Epilepsy, Remitting Focal Epilepsy (LGI2)
- Fetal-Onset Neonatal Neuroaxonal Dystrophy (MFN2)
- Hypomyelination and Tremors (FNIP2)
- Shaking Puppy Syndrome, X-linked Generalized Tremor Syndrome (PLP)
- Neuroaxonal Dystrophy, NAD (Spanish Water Dog Variant)
- Neuroaxonal Dystrophy, NAD (Rottweiler Variant)
- L-2-Hydroxyglutaricaciduria, L2HGA (L2HGDH)
- Neonatal Encephalopathy with Seizures, NEWS (ATF2)
- Polyneuropathy, NDRG1 Malamute Variant (NDRG1 Exon 4)
- Narcolepsy (HCRTR2 Intron 6)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 15)
- Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon
 4)
- Juvenile Laryngeal Paralysis and Polyneuropathy, Polyneuropathy with Ocular Abnormalities and Neuronal Vacuolation, POANV (RAB3GAP1, Rottweiler Variant)
- Hereditary Sensory Autonomic Neuropathy, Acral Mutilation Syndrome, AMS (GDNF-AS)
- Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 1, LPN1 (LPN1, ARHGEF10)
- ✓ Juvenile Myoclonic Epilepsy (DIRAS1)
- Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 2, LPN2 (GJA9)
- Spongy Degeneration with Cerebellar Ataxia 1, SDCA1, SeSAME/EAST Syndrome (KCNJ10)

- Spongy Degeneration with Cerebellar Ataxia 2, SDCA2 (ATP1B2)
- ✓ Dilated Cardiomyopathy, DCM1 (PDK4)
- Dilated Cardiomyopathy, DCM2 (TTN)
- Long QT Syndrome (KCNQ1)
- Cardiomyopathy and Juvenile Mortality (YARS2)
- Muscular Dystrophy (DMD Pembroke Welsh Corgi Variant)
- Muscular Dystrophy (DMD Golden Retriever Variant)
- Limb Girdle Muscular Dystrophy (SGCD, Boston Terrier Variant)
- Centronuclear Myopathy (PTPLA)
- Exercise-Induced Collapse (DNM1)
- ✓ Inherited Myopathy of Great Danes (BIN1)
- Myostatin Deficiency, Bully Whippet Syndrome (MSTN)
- Myotonia Congenita (CLCN1 Exon 7)
- Myotonia Congenita (CLCN1 Exon 23)
- Myotubular Myopathy 1, X-linked Myotubular Myopathy, XL-MTM (MTM1, Labrador Variant)
- Inflammatory Myopathy (SLC25A12)
- Hypocatalasia, Acatalasemia (CAT)
- Pyruvate Dehydrogenase Deficiency (PDP1)
- Malignant Hyperthermia (RYR1)
- ✓ Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 53)
- ✓ Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 8)
- ✓ Lundehund Syndrome (LEPREL1)
- Congenital Myasthenic Syndrome (CHAT)
- Congenital Myasthenic Syndrome (COLQ)

- ✓ Congenital Myasthenic Syndrome (COLQ)
- Paroxysmal Dyskinesia, PxD (PGIN)
- **⊘** Demyelinating Polyneuropathy (SBF2/MTRM13)
- Dystrophic Epidermolysis Bullosa (COL7A1)
- Ectodermal Dysplasia, Skin Fragility Syndrome (PKP1)
- Ichthyosis, Epidermolytic Hyperkeratosis (KRT10)
- Ichthyosis (PNPLA1)
- Ichthyosis (SLC27A4)
- Ichthyosis (NIPAL4)
- Hereditary Footpad Hyperkeratosis (FAM83G)
- Hereditary Nasal Parakeratosis (SUV39H2)
- ✓ Musladin-Lueke Syndrome (ADAMTSL2)
- Oculocutaneous Albinism, OCA (Pekingese Type)
- **⊘** Bald Thigh Syndrome (IGFBP5)
- ✓ Lethal Acrodermatitis (MKLN1)
- **▼** Ehlers Danlos (Doberman) (ADAMTS2)
- Cleft Lip and/or Cleft Palate (ADAMTS20)
- Hereditary Vitamin D-Resistant Rickets (VDR)
- Osteogenesis Imperfecta, Brittle Bone Disease (COL1A2)
- Osteogenesis Imperfecta, Brittle Bone Disease (SERPINH1)
- Osteogenesis Imperfecta, Brittle Bone Disease (COL1A1)
- Osteochondrodysplasia, Skeletal Dwarfism (SLC13A1)
- Skeletal Dysplasia 2, SD2 (COL11A2)
- Craniomandibular Osteopathy, CMO (SLC37A2)

- Raine Syndrome, Canine Dental Hypomineralization Syndrome (FAM20C)
- **⊘** Chondrodystrophy, Norwegian Elkhound and Karelian Bear Dog Variant (ITGA10)


Genetic Diversity and Inbreeding

Coefficient of Inbreeding (COI)

Genetic Result: 38%

Our genetic COI measures the proportion of your dog's genome (her genes) where the genes on the mother's side are identical by descent to those on the father's side. The higher your dog's coefficient of inbreeding (the percentage), the more inbred your dog is.

Your Dog's COI



This graph represents where your dog's inbreeding levels fall on a scale compared to both dogs with a similar breed makeup to her (the yellow dotted line) and all purebred dogs (the grey line).

Genetic Diversity and Inbreeding

More on the Science

Embark scientists, along with our research partners at Cornell University, have shown the impact of inbreeding on longevity and fertility and developed a state-of-the-art, peer-reviewed method for accurately measuring COI and predicting average COI in litters.

Citations

Sams & Boyko 2019 "Fine-Scale Resolution of Runs of Homozygosity Reveal Patterns of Inbreeding and Substantial Overlap with Recessive Disease Genotypes in Domestic Dogs" (https://www.ncbi.nlm.nih.gov/pubmed/30429214)

Chu et al 2019 "Inbreeding depression causes reduced fecundity in Golden Retrievers" (https://link.springer.com/article/10.1007/s00335-019-09805-4)

Yordy et al 2019 "Body size, inbreeding, and lifespan in domestic dogs" (https://www.semanticscholar.org/paper/Body-size%2C-inbreeding%2C-and-lifespan-in-domestic-Yordy-Kraus/61d0fa7a71afb26f547f0fb7ff71e23a14d19d2c)

About Embark

Embark Veterinary is a canine genetics company offering research-grade genetic tests to pet owners and breeders. Every Embark test examines over 200,000 genetic markers, and provides results for over 200 genetic health conditions, breed identification, clinical tools, and more.

Embark is a research partner of the Cornell University College of Veterinary Medicine and collaborates with scientists and registries to accelerate genetic research in canine health. We make it easy for customers and vets to understand, share and make use of their dog's unique genetic profile to improve canine health and happiness.

Learn more at embarkvet.com

Veterinarians and hospitals can send inquiries to veterinarians@embarkvet.com.